Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FluoroPharma To Present Phase I Study Results Of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer
FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, announced that it will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled PET tracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto.

Australia's Chief Nurse Wins ICN Presidency
The Australian Nursing Federation (ANF) warmly congratulated Rosemary Bryant - Australia"s Chief Nursing and Midwifery officer - on her appointment as President of the International Council of Nurses (ICN).
News of the day
Online Training For GP Teams Focuses On Care Plans For People With Intellectual Disability
The Royal Australian College of General Practitioners (RACGP) has released a new online learning activity designed to support general practitioners and other members of the general practice team in developing high quality care plans for people with intellectual disability, and in understanding eligibility requirements for Medicare-funded care plans.
Mental Health

China Aoxing Pharmaceutical Company Announces Completion Of Registration Trial Of Its Leading Narcotic Drug For The Treatment Of Cough

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a pharmaceutical company specializing in research, development, manufacturing and marketing of narcotic and pain-management products, announced that it has completed the registration trial with Codeine Phosphate, a compound oral solution for the treatment of acute moderate to severe cough. Top-line results from this trial are expected to be announced by the end of the third quarter of 2009. Under the regulation of China State Food and Drug Administration ("SFDA"), this drug is designated as a Class III New Medicine, or the first drug to be launched in China while already selling in other regulated territories. As a result, the product is expected to receive at least three-year market exclusivity protection after marketing clearance by the China SFDA. Assuming positive clinical results and timely regulatory approval, the company expects to launch this product in China in 2010. This registration trial is a randomized, multi-center, double-blind, positive-controlled study designed to evaluate the efficacy of a compound oral solution of codeine phosphate in 215 patient subjects with acute moderate to severe cough. "We are pleased to report the successful completion of this study, which has demonstrated excellent safety and efficacy among a significant number of patients," said Liying Yang, Vice President of Research of China Aoxing. "As we continue our analysis of the data collected in this study, we look forward to presenting the top-line results by the end of the third quarter of 2009." The prevalence rate of cough condition is approximately at 15% in China. It is estimated that over 50 million Chinese patients are seeking cough treatment, mainly caused by respiratory disorders. The market size of pharmaceutical product to address cough condition is estimated at approximately $2 billion per year with an annual growth rate of over 10% in China. China Aoxing Pharmaceutical Company, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009